Clinical Feasibility of Synthetic MRI in Multiple Sclerosis: A Diagnostic and Volumetric Validation Study

References

1. 1.↵
   2. Ma D,
   3. Gulani V,
   4. Seiberlich N, et al

   . Magnetic resonance fingerprinting. Nature 2013;495:187–92 doi:10.1038/nature11971 pmid:23486058

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Riederer SJ,
   3. Suddarth SA,
   4. Bobman SA, et al

   . Automated MR image synthesis: feasibility studies. Radiology 1984;153:203–06 doi:10.1148/radiology.153.1.6089265 pmid:6089265

   CrossRefPubMed
3. 3.↵
   2. Warntjes JB,
   3. Leinhard OD,
   4. West J, et al

   . Rapid magnetic resonance quantification on the brain: optimization for clinical usage. Magn Reson Med 2008;60:320–29 doi:10.1002/mrm.21635 pmid:18666127

   CrossRefPubMed
4. 4.↵
   2. Warntjes JB,
   3. Dahlqvist O,
   4. Lundberg P

   . Novel method for rapid, simultaneous T1, T2*, and proton density quantification. Magn Reson Med 2007;57:528–37 doi:10.1002/mrm.21165 pmid:17326183

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Krauss W,
   3. Gunnarsson M,
   4. Andersson T, et al

   . Accuracy and reproducibility of a quantitative magnetic resonance imaging method for concurrent measurements of tissue relaxation times and proton density. Magn Reson Imaging 2015;33:584–91 doi:10.1016/j.mri.2015.02.013 pmid:25708264

   CrossRefPubMed
6. 6.↵
   2. Ambarki K,
   3. Wåhlin A,
   4. Birgander R, et al

   . MR imaging of brain volumes: evaluation of a fully automatic software. AJNR Am J Neuroradiol 2011;32:408–12 doi:10.3174/ajnr.A2275 pmid:21051511

   Abstract/FREE Full Text
7. 7.↵
   2. West J,
   3. Warntjes JB,
   4. Lundberg P

   . Novel whole brain segmentation and volume estimation using quantitative MRI. Eur Radiol 2012;22:998–1007 doi:10.1007/s00330-011-2336-7 pmid:22113264

   CrossRefPubMed
8. 8.↵
   2. Ambarki K,
   3. Lindqvist T,
   4. Wåhlin A, et al

   . Evaluation of automatic measurement of the intracranial volume based on quantitative MR imaging. AJNR Am J Neuroradiol 2012;33:1951–56 doi:10.3174/ajnr.A3067 pmid:22555574

   Abstract/FREE Full Text
9. 9.↵
   2. Vågberg M,
   3. Lindqvist T,
   4. Ambarki K, et al

   . Automated determination of brain parenchymal fraction in multiple sclerosis. AJNR Am J Neuroradiol 2013;34:498–504 doi:10.3174/ajnr.A3262 pmid:22976234

   Abstract/FREE Full Text
10. 10.↵
    2. West J,
    3. Blystad I,
    4. Engström M, et al

    . Application of quantitative MRI for brain tissue segmentation at 1.5 T and 3.0 T field strengths. PLoS One 2013;8:e74795 doi:10.1371/journal.pone.0074795 pmid:24066153

    CrossRefPubMed
11. 11.↵
    2. Blystad I,
    3. Warntjes JB,
    4. Smedby O, et al

    . Synthetic MRI of the brain in a clinical setting. Acta Radiol 2012;53:1158–63 doi:10.1258/ar.2012.120195 pmid:23024181

    Abstract/FREE Full Text
12. 12.↵
    2. West J,
    3. Aalto A,
    4. Tisell A, et al

    . Normal appearing and diffusely abnormal white matter in patients with multiple sclerosis assessed with quantitative MR. PLoS One 2014;9:e95161 doi:10.1371/journal.pone.0095161 pmid:24747946

    CrossRefPubMed
13. 13.↵
    2. Dua T,
    3. Rompani P

    ; World Health Organization, Multiple Sclerosis International Federation. Atlas: Multiple Sclerosis Resources in the World, 2008. Geneva: World Health Organization; 2008
14. 14.↵
    2. Goodin DS,
    3. Bates D

    . Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler 2009;15:1175–82 doi:10.1177/1352458509107007 pmid:19737851

    Abstract/FREE Full Text
15. 15.↵
    2. Bakshi R,
    3. Thompson AJ,
    4. Rocca MA, et al

    . MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008;7:615–25 doi:10.1016/S1474-4422(08)70137-6 pmid:18565455

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Filippi M,
    3. Rocca MA

    . Multiple sclerosis: new measures to monitor the disease. Lancet Neurol 2013;12:12–13 doi:10.1016/S1474-4422(12)70288-0 pmid:23237892

    CrossRefPubMed
17. 17.↵
    2. Yushkevich PA,
    3. Piven J,
    4. Hazlett HC, et al

    . User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 2006;31:1116–28 doi:10.1016/j.neuroimage.2006.01.015 pmid:16545965

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Reuter M,
    3. Schmansky NJ,
    4. Rosas HD, et al

    . Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012;61:1402–18 doi:10.1016/j.neuroimage.2012.02.084 pmid:22430496

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Jenkinson M,
    3. Beckmann CF,
    4. Behrens TE, et al

    . FSL. Neuroimage 2012;62:782–90 doi:10.1016/j.neuroimage.2011.09.015 pmid:21979382

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Ashburner J,
    3. Friston KJ

    . Unified segmentation. Neuroimage 2005;26:839–51 doi:10.1016/j.neuroimage.2005.02.018 pmid:15955494

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Schmidt P,
    3. Gaser C,
    4. Arsic M, et al

    . An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage 2012;59:3774–83 doi:10.1016/j.neuroimage.2011.11.032 pmid:22119648

    CrossRefPubMed
22. 22.↵
    2. Vrenken H,
    3. Jenkinson M,
    4. Horsfield MA, et al

    ; MAGNIMS Study Group. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol 2013;260:2458–71 doi:10.1007/s00415-012-6762-5 pmid:23263472

    CrossRefPubMed
23. 23.↵
    2. Popescu V,
    3. Battaglini M,
    4. Hoogstrate WS, et al

    ; MAGNIMS Study Group. Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis. Neuroimage 2012;61:1484–94 doi:10.1016/j.neuroimage.2012.03.074 pmid:22484407

    CrossRefPubMed
24. 24.↵
    2. Miller DH,
    3. Barkhof F,
    4. Frank JA, et al

    . Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676–95 doi:10.1093/brain/awf177 pmid:12135961

    Abstract/FREE Full Text
25. 25.↵
    2. Simon JH

    . Brain atrophy in multiple sclerosis: what we know and would like to know. Mult Scler 2006;12:679–87 doi:10.1177/1352458506070823 pmid:17262994

    Abstract/FREE Full Text
26. 26.↵
    2. Fotenos AF,
    3. Mintun MA,
    4. Snyder AZ, et al

    . Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol 2008;65:113–20 pmid:18195148

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Barkhof F,
    3. Calabresi PA,
    4. Miller DH, et al

    . Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009;5:256–66 doi:10.1038/nrneurol.2009.41 pmid:19488083

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Molyneux PD,
    3. Filippi M,
    4. Barkhof F, et al

    . Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998;43:332–39 doi:10.1002/ana.410430311 pmid:9506550

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Fisniku LK,
    3. Brex PA,
    4. Altmann DR, et al

    . Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808–17 doi:10.1093/brain/awm329 pmid:18234696

    Abstract/FREE Full Text
30. 30.↵
    MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015;11:597–606 doi:10.1038/nrneurol.2015.157 pmid:26369511

    CrossRefPubMed
31. 31.↵
    2. Traboulsee A,
    3. Simon JH,
    4. Stone L, et al

    . Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am J Neuroradiol 2015 Nov 12. [Epub ahead of print]
32. 32.↵
    2. Warntjes JB,
    3. Tisell A,
    4. Landtblom AM, et al

    . Effects of gadolinium contrast agent administration on automatic brain tissue classification of patients with multiple sclerosis. AJNR Am J Neuroradiol 2014;35:1330–36 doi:10.3174/ajnr.A3890 pmid:24699093

    Abstract/FREE Full Text